Arcutis Biotherapeutics, Inc. Common Stock

Arcutis Biotherapeutics announced the appointment of Christopher Peetz, CEO of Mirum Pharmaceuticals, to its Board of Directors effective July 15, 2026. Peetz brings extensive biopharmaceutical leadership experience from roles at multiple companies including Onyx Pharmaceuticals and Tobira. The appointment comes as Arcutis continues to expand its...

The FDA has approved ZORYVE cream 0.3% for treating plaque psoriasis in children as young as age 2, marking the first once-daily, non-steroidal therapy for this indication. This is Arcutis' seventh FDA approval for ZORYVE in four years. The approval addresses a significant treatment gap for young children with plaque psoriasis, offering a steroid...

Arcutis Biotherapeutics director Sue-Jean Lin sold 4,946 shares worth $121,000 on June 15, 2026, under a pre-arranged trading plan. The sale reduced her stake by 15% but she retains over 27,500 shares. The insider transaction appears routine amid strong company performance, with ZORYVE revenue climbing 65% year-over-year to $105.4 million in Q1, ...

Antag Therapeutics announced the election of Keith Leonard as Chairman of its Board of Directors. Leonard brings 30 years of biopharmaceutical industry experience, including previous roles as Chairman and CEO of Unity Biotechnology and co-founder/CEO of Kythera Biopharmaceuticals. The appointment comes as Antag prepares to initiate Phase 2a trial...

Arcutis Biotherapeutics granted an aggregate of 44,000 restricted stock units to six newly hired employees as a material inducement for employment. The RSUs vest over four years with 25% vesting annually, subject to continuous employment. The grants were approved by the Compensation Committee under the company's 2022 Inducement Plan.